ArticleRadiation oncology (London, England)2026
Predictors of survival for locally advanced rectal cancer patients with poor response to neoadjuvant chemoradiotherapy.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with locally advanced rectal cancer (LARC) who respond poorly to neoadjuvant chemoradiotherapy (nCRT) represent a high-risk subgroup with inferior survival, but specific prognostic factors for this group are unclear. This study aimed to identify independent predictors of survival outcomes exclusively in poor responders.
methodsThis retrospective study included patients with LARC who exhibited a poor pathological response (ypT3-4 and/or ypN+) to nCRT between 2008 and 2024. The primary endpoint was overall survival (OS). Secondary endpoints were disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS). Prognostic factors were analyzed using univariate and multivariate Cox proportional hazards models, with a significance threshold of p < 0.05.
resultsAmong 295 poor responders (mean age 55.48 ± 12.51 years, 63.4% male), 89.8% had ≥ypT3 and 38.6% had ypN+ disease after nCRT. The median follow-up time was 42 months. The median OS was 67.4 months (95% CI: 57.9–98.2), with an estimated 3-year OS rate of 74.7%. In univariate analysis for OS, significant predictors were: age (HR 1.021, p = 0.013), distance from AV (HR 0.93, p = 0.025), lymph node (LN) ratio (HR 3.36, p = 0.002), ypN2 status (HR 2.08, p = 0.015), involved surgical margin (HR 2.59, p = 0.002), and TRG 2–3 vs. 0–1 (HR 2.24, p = 0.031). Based on multivariate analysis, independent predictors for OS were age (HR 1.044, p = 0.002), involved margin (HR 6.18, p < 0.001), ypN2 status (HR 3.02, p = 0.012), and a higher number of dissected LNs (HR 0.92, p = 0.010). In multivariate analysis, surgical margin, ypN2 status, and number of dissected LNs remained independent predictors for DFS, LRRFS, and DMFS. Additionally, the presence of PNI was a predictor of worse DFS, and advanced age predicted poorer DFS and DMFS.
conclusionsIn LARC patients who respond poorly to nCRT, survival is dominantly determined by surgical outcomes and the burden of resistant disease. Specifically, an involved resection margin, ypN2 status, and a low LN count are independent predictors of worse survival across all endpoints. These findings indicate that the quality of surgical resection is a critical modifiable factor for this high-risk group. Therefore, management should prioritize these patients for intensified adjuvant systemic therapy. Future efforts should develop preoperative tools to identify such high-risk patients earlier, enabling more aggressive neoadjuvant treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.